Top Tweets for #Neoadj
Credit to @DrArsenOsipov @DrHendifar & @CSCancerCenter team for identifying an important signature w/#DDR germline muts in #BR/LA #PDAC receiving #neoadj chemo #ASCO24
Check out abstr # 4164
Poster bd # 144
6/1/24 Hall A 1:30 pm CDT
https://t.co/uKIyKmH3NB
@ASCOPost @ASCO
🧬Germline testing and variants in GI cancers
Abstracts in #ASCO24 @ASCO
✅4164-In patients with pancreatic cancer undergoing neoadjuvant therapy, patients with germline DDR mutations have a significantly prolonged DFS and OS
✅e16366: Only 30% (69/223) of patients with panreatic cancer had genetic counseling referrals, an improved rate compared to last year
✅e22530- Video assisted point-of-care genetics education may help uptake of genetic testing in pancreatic cancer
✅10602- Pathogenic germline variants were detected in 17% of patients with young onset GI cancers tested
✅12119-Among 8,640 samples genotyped for DPYD and UGT1A1, DPYD variants with reduced or no function were observed in 6% of all samples
✅e22534- Among the pts tested in a Thailand CRC cohort, 27.8% carried P/LP germline variants
✅10588- 5.3% of gastric, 5.6% of gastroesophageal junction and 5.0% of esophageal cancer patients had P/LP germline variants in a Chinese cohort tested, especially in HRR genes.
@JCO_ASCO @JCOPO_ASCO @labgenehub @TheACMG @NCIEpiTraining @PanCAN
#cancer #oncology #genetics #MedX #GI
Perioperative immunotherapy for NSCLC: practical application of emerging data and new challenges.
Clin Lung Cancer 📖 DOI 👉🏻 https://t.co/I4GpuSnvOV
#nsclc #immunotherapy #chemoio #resectable #periop #adjuvant #neoadj #lcsm
@_katelynatkins frames the landscape of #neoadj #TNT approaches in locally advanced #rectalcancer based on intent of operative vs #NOM then selective #RT omission or not
5th Annual @CedarsSinai #GI Tumor Conf https://t.co/4eS8q0RCip…
@OncoAlert
@SoMeCME 2 other trials of interest in this space were: NADIM2 and PEARLS:
#NADIM2 @MARIANOPROVENCI presented @ASCO #ASCO22
➡️ #Neoadj + #Adj nivolumab
1️⃣ endpt: pCR- 36.8% v 6.9 %
2️⃣ enpt: PFS: NR vs 18.3 mos #NSCLCBriefs @SoMeCME @OncoAlert
Beautiful #neoadj paper by our #NADIM colleagues Marta Casarrubios, @MARIANOPROVENCI and @CruzAPhD from @gecp_org #LCSM #neutrophilsareimporta! @JITC https://t.co/YPdDp63QIs
ES01. Immune Checkpoint Inhibitors - Implications for Cure @IASLC #NACLC22, amazing talks by
1. Dr. Cascone @MDAndersonNews on neoadj vs adj #IO!
2. Dr. Husain @UChicago on imp of #pathology!
3. @HosseinBorghaei on characteristics of pts #neoadj #IO!
@daikisoma_uf There’s clearly a role for hepatectomy in SELECT pts with PVTT. However, this study compared against Sorafenib, and we now have many more active drugs in #HCC. IMO, this argues for #neoadj systemic to select PVTT patients who may benefit most from rsxn. Anyone feel differently?
#ESMO22 Abstract LBA6: Our Dr. Sapna Patel presents data supporting neoadjuvant immunotherapy for patients with high-risk melanoma.
“It's not just what you give, it's when you give it,” Patel says: https://t.co/skZKRtLJTj @DrSapnaPatel @SWOG #ESMO22 #EndCancer
About #train2 trial in #neoadj setting, any diff btw TCHP and carbotaxol-HP (d1➕d8) in pCR? I think weekly protocol is better tolerated @curijoey @hoperugo @DrRBarroso @PTarantinoMD . Any trial’s author in #MedTwitter ?
🚨The miracle of #Dostarlimab(anti-PD-1 drug) in the #neoadj setting of #rectalcancer
���12 Patients with #MMRd
👉stage II/III rectal adenocarcinoma
👉Dostarlimab administered for 6 months
‼️100% CR!!
Waiting for further and larger trials
https://t.co/JgUGiHugMp
"@Neoadjuvant #clinicaltrials provide a window of opportunity for cancer drug discovery" @NatureMedicine @MattGalsky @DDoroshow @MiriamMerad describe how #neoadj platforms help understanding therapies’ #MOA,and need for a paradigm shift in trial design @OncoAlert @HemOncFellows
Lastly, the debate between #neoadj vs adj treatments continue, with increasing emhpasis on #biomarkers, #ctDNA! Exciting times in perioperative #NSCLC #LCSM, and i am hopeful for patients and improvement in outcomes. 🙏 @myESMO @HwakeleeMD @MartinReck2 @LuisPaz_Ares @OncoAlert
Have we reached the point where what we do OUTSIDE the OR matters more in terms of reducing surgical complications than what we do INSIDE the OR. @PREHABmontreal #neoadj #lcsm
This RCT comparing laparoscopic and robotic gastrectomy for #gastriccancer suggests that robotic gastrectomy is unable to reduce postoperative intra-abdominal complications https://t.co/cnnFECxF31
The visionary leader is Dr Franco Carli from our @mcgillanesth department who heads up @PREHABmontreal. He turned the longer Canadian wait times to #Surgery into productive time well spent. Now with #neoadj therapy we don’t have to delay cancer therapy at all! #LCSM #TSSMN
@LFerri123 Your team has a very impressive pre-hab & ERAS program. Leaders in this space. Kudos!
@LFerri123 @DoctorJSpicer
I have to say that with the phenomenal work of Dr Franco Carli’s team @PREHABmontreal our #neoadj patients look better after than before! @GBaldini18 @CodeVie_Life #lcsm #tssmn. Have a look at our early data at #ASCO21 led by our tremendous graduating fellow @SeverinSchmid
@FordePatrick @BrendonStilesMD @DoctorJSpicer These youthful pics must have been taken before the patient started neoadj therapy
According to @BrendonStilesMD this is how a thoracic surgeon looks:
Before By the time
👇 👇
Oncologist is done with delivering neoadj tx
#ESMO20 Open questions for #neoadj chemo+anti-PD(L)1 in #TNBC:
🟣 Long term benefit
🟣 Role of pCR
🟣 PDL1 status & long term outcome
🟣 Optimal chemo regimen
🟣 Contribution of adj. CIT th
🟣 Optimal pts selection
#Oncoalert
Day2 #ESMO20 #OncoAlertTopTweet 🚨
@matteolambe from @unigenova @SanMartino_Ge
Discussing: #IMpassion031
#neoadj #atezolizumab + #chemotherpay in early #TNBC #breastcancer #BCSM
@weoncologists
Friends at #ESMO20
A pleasure to introduce our @OncoAlert 🚨Colleague @matteolambe 👨⚕️🇮🇹 from @unigenova @SanMartino_Ge Discussing:
#IMpassion031
#neoadj #atezolizumab + #chemotherpay in early #TNBC #breastcancer
Best,
@weoncologists
#BCSM
1. B) #IMPassion031 studies #neoadj #atezolizumab + chemo in early #TNBC showed #pCR in 57.6% pts with atezo+chemo vs 41.1% benefit regardless of PD-L1 status
Current SOC: #Neoadj #Chemo, algorithm below cc: @UpToDate, discussion by @matteolambe @OncoAlert https://t.co/kvftodaXYK
Friends at #ESMO20
A pleasure to introduce our @OncoAlert 🚨Colleague @matteolambe 👨⚕️🇮🇹 from @unigenova @SanMartino_Ge Discussing:
#IMpassion031
#neoadj #atezolizumab + #chemotherpay in early #TNBC #breastcancer
Best,
@weoncologists
#BCSM
As usual, great Professor @matteolambe from @UniGenova @SanMartino_Ge discussing #neoadj #Atezolizumab in #TNBC @OncoAlert #ESMO20 #BCSM
Friends at #ESMO20
A pleasure to introduce our @OncoAlert 🚨Colleague @matteolambe 👨⚕️🇮🇹 from @unigenova @SanMartino_Ge Discussing:
#IMpassion031
#neoadj #atezolizumab + #chemotherpay in early #TNBC #breastcancer
Best,
@weoncologists
#BCSM
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.8M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
111.1M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.8M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91M followers
KATY PERRY
@katyperry
87.9M followers
Taylor Swift
@taylorswift13
81.8M followers
Lady Gaga
@ladygaga
73.3M followers
Virat Kohli
@imvkohli
70.3M followers
Kim Kardashian
@kimkardashian
69.9M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64M followers
Neymar Jr
@neymarjr
63.1M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
61M followers
X
@x
60.8M followers